Spruce Biosciences Inc
SPRB8.375USD
-0.660-7.33%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
62.87KMarket Cap
LossP/E TTM
More Details of Spruce Biosciences Inc Company
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.
Company Info
Ticker SymbolSPRB
Company nameSpruce Biosciences Inc
IPO dateOct 09, 2020
CEODr. Javier Szwarcberg, M.D.
Number of employees21
Security typeOrdinary Share
Fiscal year-endOct 09
Address611 Gateway Boulevard, Suite 740
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone14156554168
Websitehttps://sprucebio.com/
Ticker SymbolSPRB
IPO dateOct 09, 2020
CEODr. Javier Szwarcberg, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Independent Director
Independent Director
--
--
Dr. Kirk Ways, M.D., Ph.D.
Dr. Kirk Ways, M.D., Ph.D.
Interim Chief Medical Officer, Director
Interim Chief Medical Officer, Director
--
--
Mr. Samir M. Gharib, CPA
Mr. Samir M. Gharib, CPA
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Percival Barretto-Ko
Mr. Percival Barretto-Ko
Independent Director
Independent Director
--
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Javier Szwarcberg, M.D.
Dr. Javier Szwarcberg, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Camilla V. Simpson
Ms. Camilla V. Simpson
Independent Director
Independent Director
--
--
Mr. Daniel K. (Dan) Spiegelman
Mr. Daniel K. (Dan) Spiegelman
Independent Director
Independent Director
--
--
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Independent Director
Independent Director
--
--
Dr. Kirk Ways, M.D., Ph.D.
Dr. Kirk Ways, M.D., Ph.D.
Interim Chief Medical Officer, Director
Interim Chief Medical Officer, Director
--
--
Mr. Samir M. Gharib, CPA
Mr. Samir M. Gharib, CPA
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Percival Barretto-Ko
Mr. Percival Barretto-Ko
Independent Director
Independent Director
--
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Javier Szwarcberg, M.D.
Dr. Javier Szwarcberg, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Sep 16
Updated: Tue, Sep 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
HealthCap AB
7.05%
Armistice Capital LLC
5.14%
RiverVest Venture Partners, LLC
2.77%
Acadian Asset Management LLC
2.48%
Ikarian Capital LLC
2.37%
Other
80.20%
Shareholders
Shareholders
Proportion
HealthCap AB
7.05%
Armistice Capital LLC
5.14%
RiverVest Venture Partners, LLC
2.77%
Acadian Asset Management LLC
2.48%
Ikarian Capital LLC
2.37%
Other
80.20%
Shareholder Types
Shareholders
Proportion
Venture Capital
9.82%
Hedge Fund
7.50%
Investment Advisor/Hedge Fund
3.72%
Individual Investor
2.32%
Other
76.63%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
88
253.92K
45.09%
-361.84K
2025Q1
95
22.07M
52.76%
-20.96M
2024Q4
99
24.56M
59.47%
-18.72M
2024Q3
101
23.45M
56.77%
-19.98M
2024Q2
107
23.28M
56.39%
-18.72M
2024Q1
131
24.69M
59.95%
-15.12M
2023Q4
118
35.07M
86.32%
-2.09M
2023Q3
122
34.74M
85.52%
-5.50M
2023Q2
128
34.84M
85.77%
-7.44M
2023Q1
133
36.55M
91.97%
+3.61M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
HealthCap AB
2.98M
7.05%
--
--
Apr 01, 2025
Armistice Capital LLC
2.17M
5.14%
--
--
Apr 01, 2025
RiverVest Venture Partners, LLC
1.17M
2.77%
-1.77M
-60.20%
Jan 07, 2025
Acadian Asset Management LLC
1.05M
2.48%
--
--
Mar 31, 2025
Ikarian Capital LLC
1.00M
2.37%
--
--
Mar 31, 2025
Worth Venture Partners, LLC
526.93K
1.25%
+224.86K
+74.44%
Dec 31, 2023
Szwarcberg (Javier B M.D.)
467.19K
1.11%
--
--
Apr 01, 2025
Gharib Samir M
350.55K
0.83%
--
--
Apr 01, 2025
Charlton (Ralph William III)
161.34K
0.38%
--
--
Apr 01, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
